- Credit Type: CPE
- Credit Amount: 1.00
- Cost: $5.00
- Release: Feb 9, 2015
- Expires: Oct 23, 2017
- Estimated Time to Complete:
- System Requirements:
Average User Rating:
BMT/Hematology Clinical Pharmacist
Assistant Adjunct Professor
Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Needs StatementWith the approval in many countries of nilotinib and dasatinib for frontline therapy in chronic myeloid leukemia, clinicians now have to make a difficult choice. Because none of the 3 available tyrosine kinase inhibitors (TKIs) have shown a clear survival advantage, they all represent reasonable choices. However, in individual patients, the case may be stronger for a particular TKI. In the younger patient, in whom the prospect of eventually achieving treatment-free remission is likely to be of great importance, dasatinib or nilotinib may be preferred, although their advantage over imatinib in this setting remains to be proven. In patients with a higher risk of transformation (which is currently based on prognostic scoring), the more potent TKIs may be preferred because they appear to be more effective at reducing the risk of transformation to BC. However, imatinib still represents an excellent choice for many chronic myeloid leukemia patients. All of these considerations need to be made in the context of the patient's comorbidities, which may lead to one or more TKIs being ruled out of contention. Whatever first choice of TKI is made, treatment failure or intolerance must be recognized early because a prompt switch to another TKI likely provides the best chance of achieving optimal response.
With several hundred thousand patients on imatinib therapy alone, pharmacists are in a unique position to impact therapy for CML with the knowledge of the similarities, differences, pharmacodynamics and importance of adherence with tyrosine kinase inhibitors.
ObjectivesUpon Completion of this activity Pharmacist will be able to:
1. Identify the role of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)
2. Discuss the limitations of first and second generation TKIs in patients that are resistant or intolerant to prior TKI therapy
3. Evaluate the impact of the novel third generation TKI on the management of Philadelphia chromosome positive leukemia with the BCR-ABL T315I mutation
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This knowledge-based activity has been assigned UAN 0022-0000-15-016-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.
Faculty DisclosureChristina Carracedo, PharmD (Speaker) has no relevant financial relationships with commercial interests.
Christina Carracedo does not intend to discuss the off-label use of a product.
No planners have any relevant financial relationships to disclose.
Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.